Docetaxel liposomal - Sun Pharma Advanced Research Company

Drug Profile

Docetaxel liposomal - Sun Pharma Advanced Research Company

Alternative Names: DICN; Docetaxel injection concentrate for nanodispersion; Docetaxel nanodispersion - Sun Pharma Advanced Research Company; Liposome-encapsulated docetaxel - Sun Pharma Advanced Research Company

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Treatment-experienced) in India (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours in India (IV, Infusion)
  • 19 Jul 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top